Science and technology advisory council - STAC
The STAC comprised of a number of independent worldwide recognised scientists and industrialists whose role was to monitor the neuromuscular diseases research of the partners and benchmark it against the worldwide state-of-the-art.
The STAC also suggested methods to improve the efficiency of the research and the transfer of new knowledge to industry.
Ségolène Aymé
Director of Research at INSERM - Orphanet
Ségolène Aymé is a medical geneticist, Director of research at the French Institute of Health and Medical Research (INSERM). She is the executive manager of the INSERM department dedicated to information on rare diseases in Paris.
Marianne de Visser
Neurologist, Professor of Neuromuscular Disorders - Amsterdam Medical Centre
Marianne has been the leader of the neuromuscular group at the Academic Medical Centre in Amsterdam in the Netherlands for more than 20 years.
Kenneth Fischbeck
Branch Chief - NINDS
Kenneth is Chief of the Neurogenetics Branch at NINDS and a TREAT-NMD STAC member.
Roland Foisner
Univ. Prof. - Medical University of Vienna
Chair of the Division of Molecular Cell Biology, Department of Medical Biochemistry, and Medical University Vienna.
Pat Furlong
CEO, Parent Project Muscular Dystrophy - PPMD - Parent Project Muscular Dystrophy
Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD) which she founded together with other parents of young men with Duchenne in 1994.
Krzysztof Jagla
Research Director in INSERM's U384 Laboratory and Coordinator of MYORES
Research Director in INSERM's U384 Laboratory and Coordinator of MYORES.
John Porter
Program Director - National Institutes of Health - NIH
Program Director for Neuromuscular Disease at the National Institute for Neurological Disorders and Stroke (NINDS), which is an institute of the US National Institutes of Health (NIH).
Boris Sustarsic About TREAT-NMD
Websites
 |
TREAT-NMD Coordination Office: T: +44 191 241 8605 Fax: +44 191 241 8770 E: info@treat-nmd.eu TREAT-NMD is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of the European Union's FP6 under contract number LSHM-CT-2006-036825 |
 |